Status:
UNKNOWN
Acute Toxicity After Moderate Hypo-fractionated Intensity Modulated Radiotherapy IMRT or Prostate Cancer
Lead Sponsor:
hanan fawzy
Conditions:
Radiation Toxicity
Eligibility:
MALE
40+ years
Brief Summary
External radiation techniques (EBRT) is considered one of the primary therapies for patients of all risk classifications of prostate cacer . EBRT aims to control tumor growth while keeping acute and l...
Detailed Description
Patients and methods This is a prospective study of at least 50 patients to record acute and late toxicity using moderate hypo-fractionation with simultaneous integrated boost (SIB) IMRT for Prostate ...
Eligibility Criteria
Inclusion
- \- Age \>40 Pathologically proved prostate cancer Patients with unfavorable intermediate, High. very high risk groups and N1disease (Metastases in regional node(s)
Exclusion
- Patients with prior pelvic irradiation. history of collagen vascular . inflammatory bowel disease. Double malignancy.
Key Trial Info
Start Date :
July 25 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 12 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05265364
Start Date
July 25 2022
End Date
December 12 2024
Last Update
October 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Oncology and Nuclear Medicin Mansoura University
Al Mansurah, Egypt